Phaseline

Companies › JYAMS PET Research & Development

JYAMS PET Research & Development: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 3; Neurology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
[18F]-APN-1607
Positron emission tomography (PET) imaging agent for detecting amyloid-beta pathology in A
APPPhase 3Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia; Alzheimer's DiseaseDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07422857[18F]-APN-1607Phase 3Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) DementiaNeurologyDec 2026
NCT07752784[18F]-APN-1607Phase 3Alzheimer's DiseaseNeurologyApr 2027

Targets

APP (1)

Companies with the same targets

Alnylam Pharmaceuticals Roche Eli Lilly Eisai Acumen Pharmaceuticals Amyloid Solution HTA Nuravax

Companies built like this

Bigespas Longboard Pharmaceuticals TriGemX Bio Zogenix ML Bio Solutions

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.